Literature DB >> 24313893

Angiostatic effects of NK cell-derived IFN-γ counteracted by tumour cell Bcl-xL expression.

R P A Wallin1, V S Sundquist, E Bråkenhielm, Y Cao, H-G Ljunggren, A Grandien.   

Abstract

Anti-apoptotic proteins that block death receptor-mediated apoptosis favour tumour evasion of the immune system, leading to enhanced tumour progression. However, it is unclear whether blocking the mitochondrial pathway of apoptosis will protect tumours from immune cell attack. Here, we report that the anti-apoptotic protein Bcl-xL , known for its ability to block the mitochondrial pathway of apoptosis, exerted tumour-progressive activity in a murine lymphoma model. Bcl-xL overexpressing tumours exhibited a more aggressive development than control tumours. Surprisingly, Bcl-xL protection of tumours from NK cell-mediated attack did not involve protection from NK cell-mediated cytotoxicity. Instead, Bcl-xL -blocked apoptosis resulting from hypoxia and/or nutrient loss associated with the inhibition of angiogenesis caused by NK cell-secreted IFN-γ. These results support the notion that NK cells may inhibit tumour growth also by mechanisms other than direct cytotoxicity. Hence, the present results unravel a pathway by which tumours with a block in the mitochondrial pathway of apoptosis can evade the immune system.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24313893     DOI: 10.1111/sji.12134

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  3 in total

1.  Aging influences the response of T cells to stimulation by the ellagitannin, oenothein B.

Authors:  Andrew G Ramstead; Igor A Schepetkin; Kimberly Todd; James Loeffelholz; James G Berardinelli; Mark T Quinn; Mark A Jutila
Journal:  Int Immunopharmacol       Date:  2015-04-15       Impact factor: 4.932

2.  Improved Antitumor Efficacy of Combined Vaccine Based on the Induced HUVECs and DC-CT26 Against Colorectal Carcinoma.

Authors:  Qiushuang Zhang; Chao Xie; Dongyu Wang; Yi Yang; Hangfan Liu; Kangdong Liu; Jimin Zhao; Xinhuan Chen; Xiaoyan Zhang; Wanjing Yang; Xiang Li; Fang Tian; Ziming Dong; Jing Lu
Journal:  Cells       Date:  2019-05-22       Impact factor: 6.600

Review 3.  Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation.

Authors:  Zhihui Dou; Dapeng Zhao; Xiaohua Chen; Caipeng Xu; Xiaodong Jin; Xuetian Zhang; Yupei Wang; Xiaodong Xie; Qiang Li; Cuixia Di; Hong Zhang
Journal:  J Exp Clin Cancer Res       Date:  2021-06-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.